Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
This study is ongoing, but not recruiting participants.
Study NCT00030849 Information provided by National Cancer Institute (NCI)
First Received: February 14, 2002 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Additional conditions recognized in this trial
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Mycosis Fungoides
Sezary Syndrome
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
recombinant interferon alfa
bexarotene
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Type I, Recombinant
Interferon-alpha
Interferons
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Anticarcinogenic Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
